How much funding has Nerre Therapeutics raised?

Nerre Therapeutics has raised $18.4M in total funding, most recently a series a round.

When was Nerre Therapeutics founded?

Nerre Therapeutics was founded in 2012.

Where is Nerre Therapeutics headquartered?

Nerre Therapeutics is headquartered in Stevenage, United Kingdom.

What industry is Nerre Therapeutics in?

Nerre Therapeutics operates in Biotech, Healthcare.

Nerre Therapeutics

Stevenage, United Kingdom · Founded 2012 · $18.4M raised

Biotech

Healthcare

Headquarters: Stevenage
Founded: 2012
Website: nerretherapeutics.com

Total Funding: $18.4M
Last Round: $18.4M Series ANov 2012
Rounds: 1

About

NeRRe Therapeutics is a Stevenage, UK-based clinical-stage biotechnology company focused on developing neurokinin receptor antagonists. Founded in 2012 as a spinout from GSK, which transferred its NK antagonist portfolio and associated intellectual property to NeRRe, the company has built a unique pipeline targeting conditions caused by neuronal hypersensitivity. Led by CEO Mary Kerr—whose team previously sold sister company KaNDy Therapeutics to Bayer for $425M upfront—NeRRe is backed by Advent Life Sciences, Columbus Venture Partners, Forbion Capital Partners, Fountain Healthcare Partners, and OrbiMed Advisors. The company's website now displays a notice that it has ceased trading.

Summary

Nerre Therapeutics is a Biotech company based in Stevenage, United Kingdom, founded in 2012. It has raised $18.4M in total across 1 round, most recently a $18.4M Series A round in Nov 2012.